Maria Cristina Mingari
Overview
Explore the profile of Maria Cristina Mingari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
7769
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barabino S, Montaldo E, Mingari M, Mazzotta C, Giuffrida S, Rolando M
Eur J Ophthalmol
. 2021 Sep;
32(4):2452-2458.
PMID: 34585595
Purpose: To evaluate the effect of tapered doses of loteprednol-etabonate in dry eye disease patients. Materials And Methods: Dry eye and treatment outcomes were assessed by Schirmer I test, tear...
12.
Quatrini L, Della Chiesa M, Sivori S, Mingari M, Pende D, Moretta L
Eur J Immunol
. 2021 Apr;
51(7):1566-1579.
PMID: 33899224
NK cells are cytotoxic components of innate lymphoid cells (ILC) that provide a first line of defense against viral infections and contribute to control tumor growth and metastasis. Their function...
13.
Sullivan L, Nguyen T, Harpur C, Stankovic S, Kanagarajah A, Koutsakos M, et al.
Sci Immunol
. 2021 Apr;
6(58).
PMID: 33893172
Human cytomegalovirus (CMV) infection can stimulate robust human leukocyte antigen (HLA)-E-restricted CD8 T cell responses. These T cells recognize a peptide from UL40, which differs by as little as a...
14.
Damele L, Amaro A, Serio A, Luchetti S, Pfeffer U, Mingari M, et al.
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33467134
The dysregulation of epigenetic modifications has a well-established role in the development and progression of hematological malignancies and of solid tumors. In this context, EZH1/2 inhibitors have been designed to...
15.
Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer
Sivori S, Della Chiesa M, Carlomagno S, Quatrini L, Munari E, Vacca P, et al.
Front Immunol
. 2020 Oct;
11:2156.
PMID: 33013909
The highly destructive mechanisms by which the immune system faces microbial infections is under the control of a series of inhibitory receptors. While most of these receptors prevent unwanted/excessive responses...
16.
Pietra G, Mingari M, Moretta L
Clin Cancer Res
. 2020 Aug;
26(20):5274-5275.
PMID: 32817077
IL15 and TIGIT blockade enhances the natural killer (NK) cell-mediated activity against MHC-I-deficient melanoma both and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT...
17.
Sivori S, Pende D, Quatrini L, Pietra G, Della Chiesa M, Vacca P, et al.
Mol Aspects Med
. 2020 Aug;
80:100870.
PMID: 32800530
Cells of the innate immunity play an important role in tumor immunotherapy. Thus, NK cells can control tumor growth and metastatic spread. Thanks to their strong cytolytic activity against tumors,...
18.
Meazza R, Falco M, Loiacono F, Canevali P, Della Chiesa M, Bertaina A, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32764469
NK cells can exert remarkable graft-versus-leukemia (GvL) effect in HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Here, we dissected the NK-cell repertoire of 80 pediatric acute leukemia patients previously reported to...
19.
Barberi C, De Pasquale C, Allegra A, Sidoti Migliore G, Oliveri D, Loiacono F, et al.
Blood Adv
. 2020 May;
4(10):2297-2307.
PMID: 32453840
Natural killer (NK) cells represent innate effector cells potentially able to play a role during the immune response against multiple myeloma (MM). To better define the distribution and the specific...
20.
Quatrini L, Vacca P, Tumino N, Besi F, Di Pace A, Scordamaglia F, et al.
J Allergy Clin Immunol
. 2020 May;
147(1):349-360.
PMID: 32417134
Background: Programmed cell death protein 1 (PD-1)-immune checkpoint blockade has provided significant clinical efficacy across various types of cancer by unleashing both T and natural killer (NK) cell-mediated antitumor responses....